Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Bausch Health Americas, Inc.
- Study ID
- NCT07428538
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Hepatitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Larsucosterol — DRUGLarsucosterol intravenous infusion.
- Placebo — DRUGMatching-placebo (sterile water for injection) intravenous infusion.
Study Details
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score greater than or equal to (\>=) 32 and Model for End-stage Liver Disease (MELD) scores 21-30, inclusive.
Key Dates
- Start date
- Jan 29, 2026
- Status verified
- May 2026
- Primary completion
- Nov 30, 2027
- Completion
- Feb 29, 2028
Study Design
- Enrollment
- 350 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Larsucosterol 30 mgParticipants will receive Larsucosterol 30 milligrams (mg) intravenous infusion on Day 1.
- Placebo Comparator: PlaceboParticipants will receive intravenous infusion of placebo matched to Larsucosterol on Day 1.
Primary Outcome Measure
Transplant Free Survival up to Day 90 [ Time Frame: Up to Day 90 ]
Central Contacts
- Varsha Bhatt707-230-1712
- Natalie Pastelak445-242-7581
Locations (48)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham (UAB) Hospital· Birmingham, ALBanner - University Medical Center, Phoenix, Arizona· Phoenix, AZMayo Clinic - Phoenix· Phoenix, AZSouthern California GI & Liver Centers - Coronado· Coronado, CACedars Sinai Medical Center· Los Angeles, CAUCLA Health - Ronald Reagan Medical Center· Los Angeles, CA